CellAction (Cell therapy Acceleration and Innovation) is the cell and gene therapy platform of the Paris-Saclay Cancer Cluster (PSCC) at Institut Curie. A first in France, CellAction enables collaborative projects to be launched with industrial partners on a national and international scale. The aim is to accelerate the development of optimized cell and gene therapies.
CellAction is founded on the centralization of key expertise required for the drug development process:
- Institut Curie's highly qualified medical-scientific teams
- Cutting-edge technologies for in vitro and in vivo testing
- Experienced advisors on business development and processes.
This integrated structure makes it possible to launch projects for the development of innovative cell and gene therapies, from basic research through to their transfer to the clinic and delivery to patients.
Company Details
- Employees
- 7
- Founded
- -
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Cellaction Questions
Cellaction's website is https://institut-curie.org/cellaction-unique-laboratory-access-cell-and-gene-therapies
Cellaction's LinkedIn profile is https://www.linkedin.com/company/cellaction
Cellaction has
7 employees.
View email and phone details for 7
employees at Cellaction.
Cellaction's industry is
Research Services
Cellaction's top competitors are
Paris Saclay Cancer Cluster (Pscc),
Alaya.bio,
Latus Bio,
Biovalley France,
Institut Du Cerveau – Paris Brain Institute,
Genother,
Gustave Roussy,
Cellforcure By Seqens,
Orakl Oncology,
Institut Curie.
Cellaction's categories are Research Services
Cellaction's founding year is 2024
